Indications
Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.
Composition
- Active substance
- belumosudil mesilate
- International name (INN)
- belumosudil
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rezurock
- Active substance
- belumosudil mesilate
- ATC code
- L04AA48
- Therapeutic area
- Graft vs Host Disease